0001209191-14-077088.txt : 20141219
0001209191-14-077088.hdr.sgml : 20141219
20141219173421
ACCESSION NUMBER: 0001209191-14-077088
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141217
FILED AS OF DATE: 20141219
DATE AS OF CHANGE: 20141219
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC
CENTRAL INDEX KEY: 0001358403
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 850
CITY: HOUSTON
STATE: TX
ZIP: 77030
BUSINESS PHONE: (832) 384-1100
MAIL ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 850
CITY: HOUSTON
STATE: TX
ZIP: 77030
FORMER COMPANY:
FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Remeditex Ventures LLC
CENTRAL INDEX KEY: 0001627363
STATE OF INCORPORATION: TX
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36783
FILM NUMBER: 141300796
BUSINESS ADDRESS:
STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601
CITY: DALLAS
STATE: TX
ZIP: 75201
BUSINESS PHONE: (214) 506-2662
MAIL ADDRESS:
STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601
CITY: DALLAS
STATE: TX
ZIP: 75201
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-12-17
0
0001358403
BELLICUM PHARMACEUTICALS, INC
BLCM
0001627363
Remeditex Ventures LLC
2101 CEDAR SPRINGS ROAD, SUITE 601
DALLAS
TX
75201
0
0
1
0
Warrant to Purchase Series C Preferred Stock (right to buy)
6.00
2014-12-17
4
X
0
271055
0.00
D
2014-08-22
2019-08-22
Series C Preferred Stock
271055
0
D
Series C Convertible Preferred Stock
2014-12-17
4
X
0
271055
A
Common Stock
159444
159444
D
Upon the date immediately following the date of the effectiveness of the initial public offering of the Issuer, on or prior to March 31, 2015, the warrants will be terminated if not previously exercised.
The Series C Convertible Preferred Stock ("Preferred Stock") are convertible into the Issuer's common stock at a conversion rate of 1 share of common stock for each 1.7 shares of Preferred Stock and have no expiration date.
By: /s/ Brett A. Ringle, President
2014-12-19